secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021198
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports Q1 net loss $10.8M; clinical and financing updates on tegoprubart
--------------------------------------------------------------------------------

- Net loss of $10.8M ($0.75/share) vs $9.9M ($0.69) in Q1 2022; R&D expenses rose to $8.1M.
- Cash $46.5M at March 31; second-quarter financing provided $35M upfront (up to $185M) to fund Phase 2 BESTOW.
- Phase 1b kidney transplant data (3 patients): no acute rejection; mean eGFR >70 mL/min/1.73m2 at timepoints up to 31 weeks.
- Phase 2a IgAN study: tegoprubart safe and well tolerated; no serious/severe AEs; 4 patients completed ≥24 weeks.
- Phase 2 BESTOW trial expected to initiate mid-2023; updated Phase 1b data anticipated late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023021198/0000950170-23-021198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023021198/eldn-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer